华安恒生生物科技ETF 9月1日发行 锚定中国医药行业“硬核”成长赛道

Group 1 - The Huazhang Hengsheng Biotechnology ETF (subscription code: 159102) was launched on September 1, focusing on the biotechnology core industry and closely tracking the Hengsheng Biotechnology Index, which covers a complete industry chain including pharmaceuticals, biotechnology, drug distribution, and medical devices [1] - The Hengsheng Biotechnology Index, launched in December 2019, has undergone multiple upgrades and is characterized by a high concentration in the innovative drug and CXO (medical research outsourcing) sectors, with weights of 61% and 19% respectively [1] - The biotechnology sector is defined as a comprehensive science and technology that utilizes biological characteristics and functions to solve problems in medicine, agriculture, and the environment, and can be divided into four sub-sectors: innovative drugs, CXO, medical devices, and AI+medical [1] Group 2 - The Hengsheng Biotechnology Index is seen as a benchmark for biotechnology investment in China, driven by "innovation orientation + industry focus," and Hong Kong is the second-largest biotechnology financing center globally [2] - China’s biotechnology industry is transitioning from "following innovation" to "original breakthroughs," with the number of self-developed innovative drugs ranking first globally since 2020, projected to reach 704 by 2024 [2] - The global interest rate cut cycle benefits the high-growth biotechnology sector by reducing capital costs, and the return of international funds to Hong Kong stocks is expected to boost the valuation recovery of quality biotechnology companies [2] Group 3 - The Huazhang Hengsheng Biotechnology ETF will be managed by Ni Bin, who has over 13 years of experience in the securities and fund industry, with nearly 7 years as an investment manager [3] - Huazhang Fund has a strong influence in the index fund investment team, having launched the first index fund in China and managing a diverse range of index public funds across various asset classes [3]